Ensign Peak Advisors’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$178K Hold
3,166
﹤0.01% 1359
2025
Q4
$254K Sell
3,166
-6,100
-66% -$410K ﹤0.01% 1197
2025
Q3
$452K Sell
9,266
-5,300
-36% -$328K ﹤0.01% 1424
2025
Q2
$1.09M Hold
14,566
﹤0.01% 1199
2025
Q1
$926K Hold
14,566
﹤0.01% 1304
2024
Q4
$1.14M Hold
14,566
﹤0.01% 1242
2024
Q3
$1.17M Hold
14,566
﹤0.01% 1231
2024
Q2
$1.21M Hold
14,566
﹤0.01% 1164
2024
Q1
$1.24M Sell
14,566
-735
-5% -$57.7K ﹤0.01% 1176
2023
Q4
$1.31M Buy
15,301
+950
+7% +$82.1K ﹤0.01% 1176
2023
Q3
$1.29M Hold
14,351
﹤0.01% 1019
2023
Q2
$1.22M Hold
14,351
﹤0.01% 1111
2023
Q1
$1.19M Buy
14,351
+200
+1% +$16.2K ﹤0.01% 1105
2022
Q4
$1.11M Sell
14,151
-2,500
-15% -$201K ﹤0.01% 1077
2022
Q3
$1.23M Sell
16,651
-190
-1% -$13.6K ﹤0.01% 965
2022
Q2
$1.1M Hold
16,841
﹤0.01% 1072
2022
Q1
$1.06M Hold
16,841
﹤0.01% 1161
2021
Q4
$893K Sell
16,841
-24,530
-59% -$1.49M ﹤0.01% 1357
2021
Q3
$2.92M Hold
41,371
0.01% 897
2021
Q2
$2.76M Hold
41,371
0.01% 937
2021
Q1
$4.59M Sell
41,371
-9,993
-19% -$1.24M 0.01% 660
2020
Q4
$6.1M Sell
51,364
-1,300
-2% -$140K 0.01% 546
2020
Q3
$4.59M Hold
52,664
0.01% 655
2020
Q2
$4.72M Hold
52,664
0.01% 622
2020
Q1
$5.25M Buy
52,664
+8,593
+19% +$932K 0.02% 500
2019
Q4
$5.06M Buy
+44,071
New +$5.33M 0.01% 640

Other funds holding HAE

Ensign Peak Advisors's HAE Position: Q1 2026 in Review

Ensign Peak Advisors held its Haemonetics (HAE) position steady in Q1 2026 at 3,166 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Ensign Peak Advisors first reported a position in HAE in Q4 2019 and has held it in 26 quarters since. The position peaked at $6.1M in Q4 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Ensign Peak Advisors held 3,166 shares of Haemonetics worth $178K as of Q1 2026.
  • Ensign Peak Advisors left its Haemonetics share count unchanged in Q1 2026.
  • Haemonetics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #1359 holding.
  • Ensign Peak Advisors first reported a position in Haemonetics in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Haemonetics position peaked at $6.1M in Q4 2020.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.